iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...
Biomedical engineers use iPSCs to grow specialized retinal endothelial cells, successfully regenerating damaged eye blood ...
Preclinical study showed iRECs Integrated into host vascular network and revascularized the ischemic eye, rescuing the tissue.
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
BELTSVILLE, Md., June 9, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced that it has received a competitive Commercialization Award from the Maryland Stem Cell Research Fund (MSCRF). The ...
The New York Blood Center Enterprises and the Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe’s inventory of over 30,000 units, ...
Human induced pluripotent stem cell (iPSC) technology has enabled the generation of virtually any human cell type from somatic cells obtained from healthy or disease donors. This powerful platform has ...
UniXell Biotechnology Co., Ltd. ('UniXell') has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem ...
Strategic partnership integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's CDMO services, giving developers a single-source path from cell line to commercial supply. PRINCETON, N ...
Century Therapeutics, Inc. announced it will present at the ASGCT 28th Annual Meeting, taking place from May 13-17, 2025, in New Orleans. The company will showcase data related to its preclinical cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results